

## APPENDIX

11. The method of claim 3, wherein the presence of a given target polynucleotide indicates the presence of a pathogen [selected from at least], wherein the pathogen is one of a virus, a prokaryote, and a eukaryote.
12. The method of claim 11, wherein the pathogen is [selected from at least] one of HIV, specific *E. coli* strains, *Salmonella* [sp.] species, and *Haemophilus* [sp.] species.
23. The method of claim 3, wherein the fluorescent indicator is [selected from a group comprising] at least one of SYBR® Green I; thiazole orange; ethidium bromide; pico green; acridine orange; quinolinium 4-[(3-methyl-2(3H)-benzoxazolylidene) methyl]-1-[3-(trimethylammonio) propyl]-diiodide; quinolinium 4-[(3-methyl-2(3H)-benzothiazolylidene) methyl]-1-[3-(trimethylammonio) propyl]-diiodide; and chromomycin A3.
25. The method of claim 3, wherein the sample is [selected from a group comprising] at least one of whole blood, a tissue biopsy, bone marrow, semen, sputum, urine, amniotic fluid, sperm, hair, skin, and cultured cells.
36. The method of claim 28, wherein the presence of a given target polynucleotide indicates the presence of a pathogen [selected from at least], wherein the pathogen is one of a virus, a prokaryote, and a eukaryote.
37. The method of claim 36, wherein the pathogen is [selected from at least] one of HIV, specific *E. coli* strains, *Salmonella* [sp.] species, and *Haemophilus* [sp.] species.
48. The method of claim 28, wherein the fluorescent indicator is [selected from a group comprising] at least one of SYBR® Green I; thiazole orange; ethidium bromide;

pico green; acridine orange; quinolinium 4-[(3-methyl-2(3H)-benzoxazolylidene) methyl]-1-[3-(trimethylammonio) propyl]-diiodide; quinolinium 4-[(3-methyl-2(3H)-benzothiazolylidene) methyl]-1-[3-(trimethylammonio) propyl]-diiodide; and chromomycin A3.

50. The method of claim 28, wherein the sample is [selected from a group comprising] at least one of whole blood, a tissue biopsy, bone marrow, semen, sputum, urine, amniotic fluid, sperm, hair, skin, and cultured cells.

FINNEGAN  
HENDERSON  
FARABOW  
CARRETT &  
DUNNER LLP

300 I Street, NW  
Washington, DC 20005  
202.408.4000  
fax 202.408.4400  
www.finnegan.com

BEST AVAILABLE COPY